Rigosertib performed pretty much as expected but the control arm of the study lived longer than anticipated, thereby causing the negative result.
Cempra's solithromycin may have an important safety advantage over competing compounds.
A look at the myriad ways cancer immunotherapy combinations might one day benefit patients.
Sangamo benefits from a Biogen partnership, but what does it mean for rivals Bluebird and Acceleron?
Innate Pharmaceuticals is developing a promising "checkpoint inhibitor" cancer drug and is partnered with Bristol-Myers Squibb.
Infinity's B-cell malignancy drug is seen as too far behind competitors but can combination therapy make it more relevant?
TheStreet contributor David Sobek offers seven forecasts for biotech stocks in 2014.
Biotech investing rarely follows a predictable script, so here's four stocks which may surprise even the most experienced investors in 2014.
New rigosertib data to be presented next month should make investors feel more confident that Onconova has an active blood-cancer drug.
New Revlimid data to be presented next month should convince European regulators to finally approve an important expansion into front-line multiple myeloma therapy.